<DOC>
	<DOCNO>NCT00606177</DOCNO>
	<brief_summary>To investigate safety efficacy long-term administration aripiprazole perform extended administration treatment administer precede multicenter , double-blind , placebo-controlled , parallel group-comparison trial aripiprazole patient bipolar disorder experience manic mixed episode ( Study 031-06-003 , hereafter `` Study 003 '' ) double-blind manner patient complete Study 003 demonstrate drug efficacy .</brief_summary>
	<brief_title>A Multicenter , Placebo-controlled , Double-blind Investigative Extension Trial Safety Efficacy Aripiprazole Treatment Patients With Bipolar Disorder Experiencing Manic Mixed Episode</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Aripiprazole</mesh_term>
	<criteria>Trial subject men woman age 18 age 65 turn 65 trial . Subjects ability understand provide inform consent examination , observation , evaluation process specify protocol , sign informed consent form base full understanding trial . Subjects meet DSMIVTR criterion manic mixed episode diagnose `` 296.4x Bipolar I Disorder recent episode manic '' `` 296.6x Bipolar I Disorder recent episode mixed '' Subjects enrol complete Study 003 meet follow criterion demonstration drug efficacy Subjects demonstrate drug efficacy : Those subject complete Study 003 whose score CGIBP Change From Preceding Phase ( mania ) time evaluation Day 21 Study 003 ( completion ) 1 ( Very much improve ) 3 ( Minimally improve ) Subjects present clinical picture and/or history consistent DSMIVTR diagnosis : Delirium , dementia , amnestic disorder , cognitive disorder Schizophrenia psychotic disorder Personality disorder Subjects psychotic symptom clearly due another general medical condition direct physiological effect substance Subjects represent significant risk commit suicide Subjects know complication allergy aripiprazole quinolinoneskeleton compound Subjects complication neuroleptic malignant syndrome Subjects state physical exhaustion accompany condition dehydration malnutrition Subjects complication paralytic ileus Subjects complication organic brain disorder convulsive disorder , epilepsy Subjects complication diabetes</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>